col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


188 Results       Page 1

 [1] 
Elsevier: Journal of Hepatology
  original article Date Title Authors   All Authors
1 [GO] 2022―Sep―28 Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis Binu V. John, Raphaella D. Ferreira, Akash Doshi, David E. Kaplan, Tamar H. Taddei, Seth A. Spector, et al. (+4)
2 [GO] 2022―Sep―27 Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data Ying Wang, Mengke Hu, Haiyan Yang
3 [GO] 2022―Sep―05 The origin of severe hepatitis of unknown aetiology in children: SARS-CoV-2 or adenovirus? Hang Yi, Yiwen Lin, Bin Lu, Yousheng Mao
4 [GO] 2022―Aug―18 Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States Xu Gao, Fan Lv, Xinyuan He, Yunyu Zhao, Yi Liu, Jian Zu, et al. (+5)
5 [GO] 2022―Jul―20 Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, Luca S. Belli, Marina Berenguer, Maria Buti, et al. (+6)
6 [GO] 2022―Jul―09 Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines Carlos King Ho Wong, Lung Yi Mak, Ivan Chi Ho Au, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, et al. (+6)
7 [GO] 2022―Jul―08 Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Sung Hak Lee, Pil Soo Sung
8 [GO] 2022―Jul―04 SARS-CoV-2 induces pericyte procoagulant response associated with portal vein microthrombosis and intrapulmonary vascular dilations in fatal COVID-19 Alberto Lasagni, Massimiliano Cadamuro, Claudia Maria Radu, Arianna Calistri, Matteo Pilan, Clarissa Valle, et al. (+16)
9 [GO] 2022―Jul―04 Exposure to the SARS-CoV-2 spike protein in an in vitro model of steatosis enhances hepatocyte oxidative stress: implications for COVID-19 and accelerated disease progression Angus Jacobs, Katie Morgan, Steven Morley, Kay Samuel, Jonathan Fallowfield, Peter Hayes, John Plevris
10 [GO] 2022―Jul―04 Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation-a prospective six month follow-up Theresa Kirchner, Hagen Sauer, Sophia Heinrich, Agnes Bonifacius, Ruhl Louisa, Isabell Pink, et al. (+10)
11 [GO] 2022―Jul―04 TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study Eric Lawitz, Rohit Loomba, Douglas Denham, Diana Chung, Erin Quirk, Lois Lee, et al. (+2)
12 [GO] 2022―Jul―04 Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients Maria Guarino, Ilaria Esposito, Giuseppe Portella, Valentina Cossiga, Ilaria Loperto, Luca Pignata, et al. (+11)
13 [GO] 2022―Jul―04 The impact of COVID-19 on the duration of the liver transplant process in patients presenting for inpatient liver transplant evaluation Katherine Cooper, Arslan Talat, Diana Liu, Alessandro Colletta, Deepika Devuni
14 [GO] 2022―Jul―04 Impact of COVID-19 on the liver transplant activity in the US: variation by the region, etiology, and cirrhosis complications Ashwani Singal, Yong-Fang Kuo, Paul Yien Kwo, Robert Wong
15 [GO] 2022―Jul―04 Effectiveness of a central monitoring system for the continuum of care of hepatitis C in Brazil during COVID-19 pandemic Paulo Bittencourt, Liana Codes, Maria Lucia Ferraz
16 [GO] 2022―Jul―04 Hepatitis C treatment during the COVID-19 pandemic has similar efficacy with less resource utilization: analysis from the British Columbia HCV network Shirley Jiang, Jeanette Feizi, Julia MacIsaac, Edward Tam, Hin HIn Ko, Alnoor Ramji
17 [GO] 2022―Jul―04 Effects of the COVID-19 pandemic on the activity of an advanced practice nurse clinic on liver cirrhosis Martina Perez, Ann Ma, Marta Cervera, Marta Carol, Ana Belén Rubio, Sara Martinez, et al. (+11)
18 [GO] 2022―Jul―04 Impact of the COVID-19 pandemic on the incidence and type of infections in hospitalized patients with cirrhosis Berta Cuyas, Anna Huerta, Maria Poca, Edilmar Alvarado-Tapias, Anna Brujats, Eva Roman, et al. (+3)
19 [GO] 2022―Jul―04 COVID-19 positive donor for solid organ transplantation Maddalena Peghin, Paolo Antonio Grossi
20 [GO] 2022―Jul―04 New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination-a vascular liver disease group (VALDIG) initiative Raoel Maan, Aurélie Plessier, Louise China, David Patch, Anna Baiges, Juan Carlos Garcia Pagan, et al. (+12)
21 [GO] 2022―Jul―04 Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients Manuel Mendizabal, Nicolas Ducasa, Paula Benencio, Maria Margarita Anders, Fernando Cairo, Adriana Alter, et al. (+4)
22 [GO] 2022―Jul―04 Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose. Elena Diago Sempere, Ana Matilla, Carlos Rodríguez, Christie Perelló, Beatriz Minguez, Maria Varela, et al. (+10)
23 [GO] 2022―Jul―04 SARS-CoV-2 infection in liver transplant recipients-a single center case series from Romania Ioana-Alexandra Husar-Sburlan, Raluca Roxana Grigorescu, Elena Cristina Radu, Daniela Tabacelia, Madalina Florescu, Florina Nitu, et al. (+8)
24 [GO] 2022―Jul―04 Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome Michal Cohen-Naftaly, Evelin Oxtrud, Orly Sneh Arbib, Assaf Issachar, Yael Harif, Amir Shlomai, Marius Braun
25 [GO] 2022―Jul―04 Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients Yana Davidov, Victoria Indenbaum, Michal Mandelboim, Keren Asraf, Tal Gonen, Keren Tsaraf, et al. (+13)
26 [GO] 2022―Jul―04 Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients Supachaya Sriphoosanaphan, Sirinporn Suksawatamnuay, Nunthiya Srisoonthorn, Nipaporn Siripon, Panarat Thaimai, Wanwisar Makhasen, et al. (+5)
27 [GO] 2022―Jul―04 Efficacy and safety of SARS-CoV-2 vaccination in liver transplant recipients Lucy Meunier, Mathilde Sanavio, Magdalena Meszaros, Stéphanie Faure, José Ursic Bedoya, Maxime Echenne, et al. (+2)
28 [GO] 2022―Jul―04 SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine Joanna Raszeja-Wyszomirska, Maciej K. Janik, Maciej Wójcicki, Piotr Milkiewicz
29 [GO] 2022―Jul―04 Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW) Alessandra Mangia, Valeria Piazzolla, Maria Squillante, Giovanna Cocomazzi, Vito Ciciriello, Vincenzo Giambra, Nicola Serra
30 [GO] 2022―Jul―04 Long-lasting seropositivity after anti SARS-CoV-2 vaccination in pre liver transplant patients Alberto Calleri, Margherita Saracco, Renato Romagnoli, Silvia Martini
31 [GO] 2022―Jul―04 Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region Pietro Torre, Mario Masarone, Roberta Sciorio, Monica Annunziata, Roberta Coppola, Laura Staiano, et al. (+2)
32 [GO] 2022―Jul―04 Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients Liane Rabinowich, Ayelet Grupper, Inbal Houri, Sharon Levy, Merav Ben-Yehoyada, Tami Halperin, et al. (+2)
33 [GO] 2022―Jul―04 Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients Aitor Odriozola Herrán, María Del Barrio, Antonio Cuadrado, Jose Ignacio Fortea, Lidia Amigo, David San Segundo Arribas, et al. (+12)
34 [GO] 2022―Jul―04 Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study Supachaya Sriphoosanaphan, Sirinporn Suksawatamnuay, Nunthiya Srisoonthorn, Nipaporn Siripon, Panarat Thaimai, Wanwisar Makhasen, et al. (+5)
35 [GO] 2022―Jul―04 Does m-RNA vaccination protect from Sars-Cov2 (asymptomatic) infection in liver transplant recipients? Ubaldo Visco Comandini, Marzia Montalbano, Raffaella Lionetti, Paola Piccolo, Daniela Nesticò, Silvia Meschi, et al. (+6)
36 [GO] 2022―Jul―04 Third dose of SARS-COV2 mRNA-vaccine in liver transplant recipients: can it bridge the response gap? Marzia Montalbano, Raffaella Lionetti, Ubaldo Visco Comandini, Silvia Meschi, Chiara Agrati, Federica Conte, et al. (+9)
37 [GO] 2022―Jul―04 Hepatitis C screening rates by age cohort 1945-1965 in a large community health system before, during and after the COVID pandemic David Bernstein, Nitzan Roth, Ben Da, Sanjaya Satapathy, Henry Bodenheimer, Christian Kuntzen, Tai PIng Lee
38 [GO] 2022―Jul―04 Reorganizing and simplifying HCV diagnosis and treatment in special populations during COVID pandemic and beyond Paolo Scivetti, Elisa Perfetti, Lorenzo Somaini, Sarah Vecchio, Antonio Panero, Paola Zaldera
39 [GO] 2022―Jul―04 The negative impact of the pandemic on hospital admissions, morbidity and 30-day mortality for acute cirrhosis decompensation: a tertiary care perspective Kohilan Gananandan, Alexandra Phillips, Anmol Chikhlia, Hannah Old, Niharika Thakur, Konstantin Kazankov, et al. (+2)
40 [GO] 2022―Jul―04 Ectopic fat deposition in the liver and pancreas and the presence of excess visceral adipose tissue significantly increase hospitalisation risk following COVID-19 Tom Waddell, Adriana Roca-Fernandez, John McGonigle, Arun Jandor, Valentina Carapella, Helena Thomaides-Brears, et al. (+3)
41 [GO] 2022―Jul―04 A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19 David Uihwan Lee, Jason Cohen, Gregory Fan, David Hastie, Akaash Mittal, Khanh Le, et al. (+4)
42 [GO] 2022―Jul―04 The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19 Jason Cohen, David Uihwan Lee, Gregory Fan, David Hastie, Akaash Mittal, Khanh Le, et al. (+4)
43 [GO] 2022―Jul―04 Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study Peter Hunyady, Lea Streller, Darius Ruether, Sara Reinartz Groba, Dominik Bettinger, Daniel Fitting, et al. (+17)
44 [GO] 2022―Jul―04 Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial. Luis Alejandro Rosales Renteria, Hiram Jaramillo-Ramírez, Francisco Calderón-Mendieta, Jesús Camacho-Escobedo, José Manuel Avendaño-Reyes, Diana Laura López-Rubio, et al. (+4)
45 [GO] 2022―Jul―04 Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease Carlos Alventosa Mateu, Elena Guillen Botaya, Cecilia Albert-Antequera, Irene Perez Alvarez, Alejandro Fernandez Soro, Eva Sanchez Ramos, et al. (+10)
46 [GO] 2022―Jul―04 Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan Md Razeen Ashraf Hussain, Aya Sugiyama, Lindsey Hiebert, Serge Ouoba, Bunthen E, Ko Ko, et al. (+5)
47 [GO] 2022―Jul―04 Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis Lukas Hartl, Mathias Jachs, Benedikt Simbrunner, David JM Bauer, Georg Semmler, Daniela Gompelmann, et al. (+6)
48 [GO] 2022―Jul―04 COVID-19 in patients with cirrhosis: insights from the multinational LEOSS registry Jonathan Frederik Brozat, Frank Hanses, Martina Haselberger, Melanie Stecher, Michael Dreher, Lukas Tometten, et al. (+14)
49 [GO] 2022―Jul―04 The course of COVID-19 infection in patients with chronic hepatitis B and Delta Yavuz Emre Parlar, Onur Keskin, Beril Kirmizigul, Genco Gencdal, Mujdat Zeybel, Mesut Gumussoy, et al. (+2)
50 [GO] 2022―Jul―04 Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease Zobair Younossi, Yusuf Yılmaz, Mohamed El Kassas, Ajay Kumar Duseja, Saeed Sadiq Hamid, Gamal Esmat, et al. (+13)
51 [GO] 2022―Jul―04 Three COVID-19 medications-remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir-and serial liver biochemistries in 22, 456 subjects Grace Lai-Hung Wong, Vicki Wing-Ki Hui, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vincent Wai-Sun Wong
52 [GO] 2022―Jul―04 Hepatitis B birth dose coverage remains dramatically low in The Gambia and has been disrupted by the COVID-19 pandemic Gibril Ndow, Esu Ezeani, Cecile de Bezenac, Julien Randon-Furling, Umberto D’Alessandro, Yusuke Shimakawa, Maud Lemoine
53 [GO] 2022―Jul―04 Trends of alcohol-related liver disease hospitalisation during the COVID-19 pandemic Oyekoya Ayonrinde, Richard Goodheart
54 [GO] 2022―Jul―04 Progress in HCV screening in the national hepatitis C elimination program in Georgia during the COVID-19 pandemic, 2019-2021 Amiran Gamkrelidze, Alexander Turdziladze, Maia Tsreteli, Vladimer Getia, Ana Aslanikashvili, Tinatin Kuchuloria, et al. (+6)
55 [GO] 2022―Jul―04 The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada Naveed Janjua, Stanley Wong, Dahn Jeong, Mawuena Binka, Terri Buller-Tylor, Sofia Bartlett, et al. (+7)
56 [GO] 2022―Jul―04 COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation Leya Nedumannil, Sukhdeep Steven Cheema, Karl Vaz, Ronald Ma, Daryl Jones, Stephen Warrillow, et al. (+3)
57 [GO] 2022―Jul―04 Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: a retrospective cohort study Alexandra Frolkis, Meredith Borman, Matthew Sadler, Stephen Congly, Henry Nguyen, Samuel Lee, et al. (+6)
58 [GO] 2022―Jul―04 Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program Vana Sypsa, Sotiris Roussos, Efrossini Tsirogianni, Despina Trafali, Dimitra Tsiagka, Athena Gavalaki, et al. (+7)
59 [GO] 2022―Jul―04 Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia Lasha Gulbiani, Tiko Kamkamidze, Ana Gamezardashvili, George Kamkamidze, Maia Butsashvili
60 [GO] 2022―Jul―04 Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain Jorge Valencia, Pablo Ryan, Guillermo Cuevas, Julieta Domingorena, Álvaro Vicario, Marcela Villota-Rivas, Jeffrey Lazarus
61 [GO] 2022―Jul―04 COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses Maria Ines Canha, Mario Jorge Silva, Maria Azevedo Silva, Mara Costa, Rita Catarina Saraiva, André Ruge, et al. (+7)
62 [GO] 2022―Jul―04 Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis Ana Barreira, Mar Riveiro Barciela, Agustin Castiella, Álvaro Díaz-González, Maria Carlota Londoño, Indhira Perez Medrano, et al. (+5)
63 [GO] 2022―Jul―04 Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy Roberta D’Ambrosio, Giuliano Rizzardini, Massimo Puoti, Stefano Fagiuoli, Maria Paola Anolli, Claudia Gabiati, et al. (+4)
64 [GO] 2022―Jul―04 No effect of HBsAg positivity on antibody response after COVID-19 vaccine Ganbolor Jargalsaikhan, Enkhtuul Batbold, Delgersaikhan Zulkhuu, Oyungerel Lkhagva-Ochir, Uurtsaikh Baatarsuren, Myagmarjav B�azar, et al. (+13)
65 [GO] 2022―Jul―04 Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine Anand Kulkarni, Sasikala Mitnala, Sowmya Iyengar, Shashidhar Jaggaiahgari, Baqar Gora, Hardik Rugwani, et al. (+3)
66 [GO] 2022―Jul―04 mRNA COVID-19 vaccine effectiveness in liver transplant patients Muhammad Khan, Kamran Mushtaq, Deema AlSoub, Hussam Almasri, Bisher Sawaf, Saad AlKaabi, Yasser Kamel
67 [GO] 2022―Jul―04 COVID-19 vaccine induced autoimmune hepatitis-a first case series from India Sowmya Iyengar, Anand Kulkarni, Goutham Reddy Katukuri, Mithun Sharma, Nageshwar Reddy, Nagaraja Rao Padaki
68 [GO] 2022―Jul―04 Acute hepatitis after COVID-19 vaccine: case series by the International autoimmune hepatitis group (IAIHG) and the european reference network on hepatological diseases (ERN RARE-LIVER) Greta Codoni, Maria Alejandra Gracia Villamil, Albert Stättermayer, Agustin Castiella, Christoph Schramm, Jan-Philipp Weltzsch, et al. (+16)
69 [GO] 2022―Jul―04 Two different types of COVID-19 vaccines and serial liver biochemistries Grace Lai-Hung Wong, Vicki Wing-Ki Hui, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vincent Wai-Sun Wong
70 [GO] 2022―Jul―04 Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines-a multicenter european study André L. Simão, Carolina Santos Palma, Laura Izquierdo-Sánchez, Antonella Putignano, Ângela Carvalho-Gomes, Andreas Posch, et al. (+22)
71 [GO] 2022―Jul―04 Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis Binu John, Akash Doshi, Yangyang Deng, Natalie Mansour, A.Sidne Barritt, Andrew Moon, et al. (+6)
72 [GO] 2022―Jul―04 Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata Lukas Hartl, Katharina Haslinger, Martin Angerer, Mathias Jachs, Benedikt Simbrunner, David J.M Bauer, et al. (+9)
73 [GO] 2022―Jul―04 Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database Frank Tacke, Fady Tanios, Lin Xie, Deepa Malhotra, Simon Dagenais, Nino Katchiuri, Birol Emir
74 [GO] 2022―Jul―04 Cholangiopathy after severe COVID-19: what do we know so far? Valéria Ferreira de Almeida e Borges, Helma Pinchemel Cotrim, Marcelo Simão Ferreira, José Humberto Caetano Marins, Haroldo Luis Oliva Gomes Rocha, Leonardo Augusto Dias Nascimento, et al. (+2)
75 [GO] 2022―Jul―04 Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant Binu John, Raphaella Ferreira, Dustin Bastaich, Akash Doshi, Tamar H Taddei, David Kaplan, et al. (+2)
76 [GO] 2022―Jul―04 SARS-CoV-2 infection in patients with underlying chronic liver disease is associated with significantly greater risks of inpatient hospitalization, intensive care unit admission, and overall mortality Robert Wong, Yi Zhang, Mae Thamer
77 [GO] 2022―Jul―04 Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease Al-Dury Samer, Johan Waern, Anna Martner, Hevar Hamah Saed, Marko Alavanja, Johan Ringlander, et al. (+6)
78 [GO] 2022―Jul―04 Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study Massimo Iavarone, Giulia Tosetti, Floriana Facchetti, Matilde Topa, Andrea Lombardi, Roberta D’Ambrosio, et al. (+9)
79 [GO] 2022―Jul―04 Post-COVID-19 cholangiopathy: does SARS-CoV-2 play a relevant role in histopathological findings? Valéria Ferreira de Almeida e Borges, Helma Pinchemel Cotrim, Marcelo Costa Silva, Liliana Sampaio Costa Mendes, Francisco Guilherme Cancela Penna, Antônio Ricardo Cardia Ferraz de Andrade, et al. (+3)
80 [GO] 2022―Jul―04 The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients Marta Freitas, Tiago Capela, Vítor Macedo Silva, Sofia Xavier, Joana Teixeira Magalhães, Carla Maria Moura Marinho, José Cotter
81 [GO] 2022―Jul―04 Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study Kristin Jorgensen, Adity Chopra, Joseph Sexton, Anne T Tveter, Johannes R. Hov, Ingrid Jyssum, et al. (+6)
82 [GO] 2022―Jul―04 Evaluation of immune response and disease flares in metobolic-associated fatty liver disease patients following SARS-CoV-2 vaccination: a prospective cohort study Junping Shi, Qianru Zhu, Jin Gao, Jiaping Gu, Lu Shen, Jing Liu, et al. (+9)
83 [GO] 2022―Jul―04 Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis Apichat Kaewdech, Nawamin Pinpathomrat, Naichaya Chamroonkul, Teerha Piratvisuth, Pimsiri Sripongpun
84 [GO] 2022―Jul―04 Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases Hu Li, Yuting Wang, Ling Ao, Mingxia Ke, Zhi-wei Chen, Min Chen, et al. (+6)
85 [GO] 2022―Jul―04 Effects of SARS-CoV2 pandemic in a cohort of italian NAFLD patients Bernardo Stefanini, Simona Leoni, Roberta Capelli, Alice Secomandi, Luca Muratori, Fabio Piscaglia, Silvia Ferri
86 [GO] 2022―Jul―04 Lack of awareness of a NAFLD pandemic in a high risk group. Is it time to act in primary care? Maria Guerra Veloz, Kosh Agarwal, Marck Chamley, Saima Ajaz
87 [GO] 2022―Jul―04 Humoral and cellular immune responses to wild-type and omicron (B.1.1.529) SARS-CoV-2 variants following a fourth COVID-19 vaccination in liver transplant recipients and patients with autoimmune hepatitis Stavros Dimitriadis, Georgina Meacham, Sophie Irwin, Victoria Walker, Sam Murray, Zixiang Lim, et al. (+3)
88 [GO] 2022―Jul―04 T cell and humoral immune response to multiple SARS-CoV-2 variants including omicron (B1.1.529) after two doses of COVID-19 vaccine in patients with cirrhosis and liver diseases requiring immunosuppression: data from the EASL COVID-Hep network Sam Murray, Stephanie Longet, Tom Tipton, Maria Carlota Londoño, Elisa Pose, Stephen Laidlaw, et al. (+22)
89 [GO] 2022―Jul―04 Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study Thomas Marjot, Sam Murray, Elisa Pose, Zixiang Lim, Maria Carlota Londoño, Melanie Wittner, et al. (+23)
90 [GO] 2022―May―16 Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination Yakir Guri, Jürg Vosbeck, Michael Dickenmann, Alexander Jetter, Christine Bernsmeier
91 [GO] 2022―Apr―21 SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis Tobias Boettler, Benedikt Csernalabics, Henrike Salié, Hendrik Luxenburger, Lara Wischer, Elahe Salimi Alizei, et al. (+10)
92 [GO] 2022―Mar―10 Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients Pierluigi Toniutto, Edmondo Falleti, Sara Cmet, Annarosa Cussigh, Laura Veneto, Davide Bitetto, et al. (+8)
93 [GO] 2022―Mar―10 Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care Darius Ferenc Rüther, Jan Philipp Weltzsch, Christoph Schramm, Marcial Sebode, Ansgar Wilhelm Lohse
94 [GO] 2022―Mar―10 Unexplained liver test elevations after SARS-CoV-2 vaccination John Guardiola, Craig Lammert, Evgenia Teal, Naga Chalasani
95 [GO] 2021―Nov―25 Prono-SARS: Prognosis of French COVID-19 Patients in 2020-2021 François Depret, Samir Bouam, Michaël Schwarzinger, Vincent Mallet
96 [GO] 2021―Nov―20 Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease Dong Liu, Qianlong Zhang, Pinqing Bai, Jian Zhao
97 [GO] 2021―Oct―14 Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS) Francesco Paolo Russo, Manhal Izzy, Ashwin Rammohan, Varvara A. Kirchner, Tommaso Di Maira, Luca Saverio Belli, et al. (+3)
98 [GO] 2021―Oct―09 Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: time for comprehensive data analysis Liane Rabinowich, Oren Shibolet, Helena Katchman
99 [GO] 2021―Oct―02 Reply Prognosis of Covid-19 patients with chronic liver disease in France in 2020 Vincent Mallet, Michaël Schwarzinger, Vincent Mallet, Michaël Schwarzinger, Nathanaël Beeker, Samir Bouam, et al. (+6)
100 [GO] 2021―Sep―30 Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database Mikhael Giabicani, Alice Le Menestrel, Olivier Roux, Pierre-Emmanuel Rautou, Emmanuel Weiss
101 [GO] 2021―Aug―26 Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases Paul J. Thuluvath, Polly Robarts, Mahak Chauhan
102 [GO] 2021―Aug―25 New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant? Taotao Zhou, Florian Fronhoffs, Leona Dold, Christian P. Strassburg, Tobias J. Weismüller
103 [GO] 2021―Aug―24 Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk? Rodrigo Feliciano do Carmo, Carlos Dornels Freire de Souza
104 [GO] 2021―Aug―10 Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: One or Even Several Swallows Do Not Make a Summer Bril Fernando
105 [GO] 2021―Aug―03 Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: the debate is open! Maria Guarino, Valentina Cossiga, Ilaria Esposito, Furno Alessandro, Filomena Morisco
106 [GO] 2021―Jul―31 Liver injury following SARS-CoV-2 vaccination: a multicenter case series Hersh Shroff, Sanjaya K. Satapathy, James M. Crawford, Nancy J. Todd, Lisa B. VanWagner
107 [GO] 2021―Jul―19 Association of chronic liver disease with the prognosis of COVID-19 patients Junyu Long, Xinting Sang, Haitao Zhao
108 [GO] 2021―Jul―17 SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis Theresa Kirchner, Elmar Jaeckel, Christine S. Falk, Britta Eiz-Vesper, Richard Taubert
109 [GO] 2021―Jul―15 Unraveling the role of liver sinusoidal endothelial cells in COVID-19 liver injury Antonio Saviano, Thomas F. Baumert
110 [GO] 2021―Jul―10 AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY? Francesca Lodato, Anna Larocca, Antonietta D’Errico, Vincenzo Cennamo
111 [GO] 2021―Jul―08 The mRNA COVID-19 vaccine - a rare trigger of Autoimmune Hepatitis? Cathy McShane, Clifford Kiat, Jonathan Rigby, Órla Crosbie
112 [GO] 2021―Jun―24 Intravenous ketamine is a risk factor for jaundice in Covid-19 patients Vincent Mallet, Vincent Mallet, Kilian Bock, Mourad Dellagi, Marion Tano, Virginie Siorat, et al. (+30)
113 [GO] 2021―Jun―22 Comment to the letter of Bril F et al. “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?” Daniel Clayton-Chubb, Daniel Schneider, Elliot Freeman, William Kemp, Stuart K. Roberts
114 [GO] 2021―Jun―18 Autoimmune hepatitis following COVID-19 Vaccination: true causality or mere association? Chin Kimg Tan, Yu Jun Wong, Lai Mun Wang, Tiing Leong Ang, Rahul Kumar
115 [GO] 2021―Jun―17 Response to letter to the editor by Capecchi et al. “Comment to the letter of Bril F et al. “Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: Causality or Casualty?” Fernando Bril, David M. Fettig
116 [GO] 2021―Jun―12 Another case of autoimmune hepatitis after SARS-CoV-2 vaccination. Still casualty? Maria-Carlota Londoño, Jordi Gratacós-Ginès, Joaquín Sáez-Peñataro
117 [GO] 2021―Jun―09 Autoimmune hepatitis following sars-cov-2 VACCINE: MAY not be a casualty Alba Rocco, Costantino Sgamato, Debora Compare, Gerardo Nardone
118 [GO] 2021―Jun―06 Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19 Ze-yang Ding, Gan-xun Li, Chang Shu, Ping Yin, Bixiang Zhang
119 [GO] 2021―May―28 High acceptance rate of COVID-19 vaccination in liver transplant recipients Edoardo G. Giannini, Simona Marenco
120 [GO] 2021―May―25 Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients Markus Cornberg, Christiane S. Eberhardt
121 [GO] 2021―May―14 Prognosis of French COVID-19 patients with chronic liver disease: a national retrospective cohort study for 2020 Vincent Mallet, Nathanael Beeker, Samir Bouam, Philippe Sogni, Stanislas Pol, Vincent Mallet, et al. (+9)
122 [GO] 2021―May―13 Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy Matthew J. McConnell, Nao Kawaguchi, Reiichiro Kondo, Aurelio Sonzogni, Lisa Licini, Clarissa Valle, et al. (+19)
123 [GO] 2021―May―07 HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination? Javier Crespo, Álvaro Díaz-González, Joaquín Cabezas
124 [GO] 2021―May―05 Comment to the letter of Bril F et al. “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?” Pier Leopoldo Capecchi, Pietro Enea Lazzerini, Stefano Brillanti
125 [GO] 2021―Apr―24 Risk stratification in hospitalized COVID-19 patients Angela Horvath, Theresa Lind, Natalie Frece, Herbert Wurzer, Vanessa Stadlbauer
126 [GO] 2021―Apr―24 Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study Jitao Wang, Zhiyun Hou, Jianxin Liu, Ye Gu, Yunhong Wu, Zhenhuai Chen, et al. (+39)
127 [GO] 2021―Apr―24 Letter regarding “association of liver abnormalities with in-hospital mortality in patients with COVID-19 Meng-Si Luo, Guan-Jiang Huang
128 [GO] 2021―Apr―21 Reply to: Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients Manuel Rodríguez-Perálvarez, Jordi Colmenero, Magdalena Salcedo
129 [GO] 2021―Apr―21 Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty? Fernando Bril, Sameer Al Diffalha, Mark Dean, David M. Fettig
130 [GO] 2021―Apr―21 Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients Liane Rabinowich, Ayelet Grupper, Roni Baruch, Merav Ben-Yehoyada, Tami Halperin, Dan Turner, et al. (+6)
131 [GO] 2021―Apr―20 DECREASE IN VIRAL HEPATITIS DIAGNOSES DURING THE COVID-19 PANDEMIC IN THE NETHERLANDS Milan J. Sonneveld, Irene K. Veldhuijzen, Thijs van de Laar, Eline L.M. Op de Coul, Adriaan J. van der Meer
132 [GO] 2021―Mar―20 Liver Injury in COVID-19 - The culprit may not be COVID-19! Aditya Singh, Madhumita Premkumar, Virendra Singh
133 [GO] 2021―Mar―20 Progressive cholangiopathy in Covid-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered Pierre Deltenre, Christophe Moreno, Eric Trépo
134 [GO] 2021―Mar―20 Let’s leverage SARS-CoV2 vaccination to screen for hepatitis C screening in Spain, in Europe, around the world Javier Crespo, Jeffrey V. Lazarus, Paula Iruzubieta, Federico García, Javier García-Samaniego
135 [GO] 2021―Feb―21 Intravenous ketamine and progressive cholangiopathy in Covid-19 patients Vincent Mallet
136 [GO] 2021―Feb―21 PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION Alessandra Bartoli, Stefano Gitto, Pamela Sighinolfi, Carmela Cursaro, Pietro Andreone
137 [GO] 2021―Feb―07 EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients Markus Cornberg, Maria Buti, Christiane S. Eberhardt, Paolo Antonio Grossi, Daniel Shouval
138 [GO] 2021―Feb―06 Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. Gwilym J. Webb, Andrew M. Moon, Eleanor Barnes, A. Sidney Barritt, Thomas Marjot
139 [GO] 2021―Jan―26 SARS-CoV-2 infection in patients with autoimmune hepatitis Thomas Marjot, Gustav Buescher, Marcial Sebode, Eleanor Barnes, Alfred S. Barritt, Matthew J. Armstrong, et al. (+9)
140 [GO] 2021―Jan―13 Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy Andrea Giacomelli, Gabriele Pagani, Federico Conti, Cinzia Bassoli, Massimo Galli
141 [GO] 2020―Dec―20 Impact of the COVID 19 Pandemic on HCV Elimination in Spain Maria Buti, Raquel Domínguez-Hernández, Miguel Angel Casado
142 [GO] 2020―Dec―19 Association of liver abnormalities with in-hospital mortality in patients with COVID-19 Ze-yang Ding, Gan-xun Li, Lin Chen, Chang Shu, Jia Song, Wei Wang, et al. (+22)
143 [GO] 2020―Dec―16 Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD Abraham S. Meijnikman, Sjoerd Bruin, Albert K. Groen, Max Nieuwdorp, Hilde Herrema
144 [GO] 2020―Nov―20 NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues Kamran Mushtaq, Muhammad Umair Khan, Fatima Iqbal, Deema Hussam Alsoub, Hammad Shabir Chaudhry, Fateen Ata, et al. (+7)
145 [GO] 2020―Oct―30 Reply to: ‘NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression-The debate continues’ Dong Ji, Gregory Cheng, George Lau
146 [GO] 2020―Oct―20 Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points Marcos F. Fondevila, Maria Mercado-Gómez, Amaia Rodríguez, Maria J. Gonzalez-Rellan, Paula Iruzubieta, Víctor Valentí, et al. (+8)
147 [GO] 2020―Oct―09 SARS-CoV-2 massive testing: a window of opportunity to catch up with HCV elimination Javier Crespo, Álvaro Díaz-González, Paula Iruzubieta, Susana Llerena, Joaquín Cabezas
148 [GO] 2020―Oct―08 COVID-19: discovery, diagnostics and drug development Tarik Asselah, David Durantel, Eric Pasmant, George Lau, Raymond F. Schinazi
149 [GO] 2020―Oct―06 Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study Thomas Marjot, Andrew M. Moon, Jonathan A. Cook, Sherief Abd-Elsalam, Costica Aloman, Matthew J. Armstrong, et al. (+24)
150 [GO] 2020―Sep―16 Dried blood spots are a useful tool for hepatitis A screening in the pandemic areas with medical resource-limited condition Chikako Yamamoto, Junko Tanaka, Vichit Ork, Shintaro Nagashima, Channarena Chuon, Ko Ko, et al. (+2)
151 [GO] 2020―Sep―10 Health status of patients with Autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders (Belgium) Xavier Verhelst, Nicky Somers, Anja Geerts, Helena Degroote, Hans Van Vlierberghe
152 [GO] 2020―Sep―02 Covid-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall Alexandre Balaphas, Kyriaki Gkoufa, Jeremy Meyer, Andrea Peloso, Aurélie Bornand, Thomas A. McKee, et al. (+2)
153 [GO] 2020―Aug―07 Authors’ reply on HIGH RATES OF 30-DAY MORTALITY IN PATIENTS WITH CIRRHOSIS AND COVID-19 Massimo Iavarone, Roberta D’Ambrosio, Pietro Lampertico
154 [GO] 2020―Aug―07 Impact of COVID-19 on global hepatitis C elimination efforts Sarah Blach, Loreta A. Kondili, Alessio Aghemo, Zongzhen Cai, Ellen Dugan, Chris Estes, et al. (+8)
155 [GO] 2020―Aug―01 Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients. Jordi Colmenero, Manuel Rodríguez-Perálvarez, Magdalena Salcedo, Ana Arias-Milla, Alejandro Muñoz-Serrano, Javier Graus, et al. (+29)
156 [GO] 2020―Jul―27 Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination Jeffrey V. Lazarus, Camila A. Picchio, Shevanthi Nayagam, Scott Ratzan, Mark Thursz
157 [GO] 2020―Jul―13 SARS-CoV2 in patients on antiviral HBV and HCV therapy in Spain Sabela Lens, Mireia Miquel, Beatriz Mateos-Muñoz, Javier García-Samaniego, Xavier Forns
158 [GO] 2020―Jul―06 Inflammasome Activation and Pyroptosis in Lymphopenic COVID-19 Liver Patients Alexander Kroemer, Khalid Khan, Matthew Plassmeyer, Oral Alpan, M.A. Haseeb, Raavi Gupta, Thomas M. Fishbein
159 [GO] 2020―Jul―04 Reply to “Liver tests abnormalities in COVID-19: trick or treat?” Qingxian Cai, Lin Xu, Jun Chen
160 [GO] 2020―Jun―23 Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis Montserrat Fraga, Darius Moradpour, Florent Artru, Elodie Romailler, Jonathan Tschopp, Antoine Schneider, et al. (+5)
161 [GO] 2020―Jun―23 SARS-CoV-2 infection in liver-Author’s reply Yijin Wang, Fengmin Lu, Jingmin Zhao
162 [GO] 2020―Jun―20 Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis? Gabriella Assante, Roger Williams, Neil Alexander Youngson
163 [GO] 2020―Jun―20 The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research Feng Gao, Zhi-Ming Huang
164 [GO] 2020―Jun―20 Characteristics of pregnant COVID-19 patients with liver injury Guangtong Deng, Furong Zeng, Lijuan Zhang, Hui Chen, Xiang Chen, Mingzhu Yin
165 [GO] 2020―Jun―20 Letter regarding [High rates of 30-day mortality in patients with cirrhosis and COVID-19] Mohammed A. Medhat, Mohamed El Kassas
166 [GO] 2020―Jun―15 COVID-19 and Liver. Dinesh Jothimani, Radhika Venugopal, Mohammed Forhad Abedin, Ilankumaran Kaliamoorthy, Mohamed Rela
167 [GO] 2020―Jun―09 High rates of 30-day mortality in patients with cirrhosis and COVID-19 Massimo Iavarone, Roberta D’Ambrosio, Alessandro Soria, Michela Triolo, Nicola Pugliese, Paolo Del Poggio, et al. (+16)
168 [GO] 2020―Jun―02 SARS-CoV-2: is the liver merely a bystander to severe disease? Mansoor N. Bangash, Jaimin M. Patel, Dhruv Parekh, Nicholas Murphy, Rachel M. Brown, Ahmed M. Elsharkawy, et al. (+3)
169 [GO] 2020―May―28 Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2 Vincent De Smet, Stefaan Verhulst, Leo A. van Grunsven
170 [GO] 2020―May―27 Liver tests abnormalities in COVID-19: trick or treat? Edoardo Vespa, Nicola Pugliese, Daniele Piovani, Antonio Capogreco, Silvio Danese, Alessio Aghemo
171 [GO] 2020―May―23 SARS-CoV-2 related liver impairment - perception may not be the reality Cyriac Abby Philips, Rizwan Ahamed, Philip Augustine
172 [GO] 2020―May―23 An international multicentre study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise Claire Alexandra Chew, Shridhar Ganpathi Iyer, Alfred Wei Chieh Kow, Krishnakumar Madhavan, Andrea Sze Teng Wong, Karim J. Halazun, et al. (+18)
173 [GO] 2020―May―22 A Local Response to COVID-19 for Advanced Liver Disease: Current Model of Care, Challenges and Opportunities Marina Serper, Abraham Shaked, Kim M. Olthoff, Maarouf Hoteit, Brenda Appolo, K. Rajender Reddy
174 [GO] 2020―May―21 High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry Andrew M. Moon, Gwilym J. Webb, Costica Aloman, Matthew J. Armstrong, Tamsin Cargill, Renumathy Dhanasekaran, et al. (+13)
175 [GO] 2020―May―20 Lack of genetic evidence that fatty liver disease predisposes to COVID-19 Luca Valenti, Oveis Jamialahmadi, Stefano Romeo
176 [GO] 2020―May―12 Health status of patients with Autoimmune Liver Disease during SARS-CoV-2 outbreak in northern Italy Angelo Di Giorgio, Emanuele Nicastro, Camilla Speziani, Massimo De Giorgio, Luisa Pasulo, Bianca Magro, et al. (+2)
177 [GO] 2020―May―11 SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 Yijin Wang, Shuhong Liu, Hongyang Liu, Wei Li, Fang Lin, Lina Jiang, et al. (+16)
178 [GO] 2020―May―11 Reply to: ‘Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis’ Dong Ji, Enqiang Qin, George Lau
179 [GO] 2020―May―06 Reply to “Clinical characteristics of COVID-19 patients with abnormal liver tests” Qingxian Cai, Jun Chen
180 [GO] 2020―May―06 Reply to: ‘No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease’ Dong Ji, Enqiang Qin, Jing Xu, Dawei Zhang, Gregory Cheng, Yudong Wang, George Lau
181 [GO] 2020―Apr―30 No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease Louise Biquard, Dominique Valla, Pierre-Emmanuel Rautou
182 [GO] 2020―Apr―27 Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis Yu-Jie Zhou, Kenneth I. Zheng, Xiao-Bo Wang, Hua-Dong Yan, Qing-Feng Sun, Ke-Hua Pan, et al. (+5)
183 [GO] 2020―Apr―27 Clinical characteristics of COVID-19 patients with abnormal liver tests Peng Chen, Benhong Zhou
184 [GO] 2020―Apr―17 Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury Xiaolong Qi, Chuan Liu, Zicheng Jiang, Ye Gu, Guo Zhang, Chuxiao Shao, et al. (+20)
185 [GO] 2020―Apr―14 COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care Elliot B. Tapper, Sumeet K. Asrani
186 [GO] 2020―Apr―14 Characteristics of Liver Tests in COVID-19 Patients Qingxian Cai, Deliang Huang, Hong Yu, Zhibin Zhu, Zhang Xia, Yinan Su, et al. (+10)
187 [GO] 2020―Apr―10 Highlights for management of patients with Autoimmune Liver Disease during COVID-19 pandemia Ana Lleo, Pietro Invernizzi, Ansgar W. Lohse, Alessio Aghemo, Marco Carbone
188 [GO] 2020―Apr―08 Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis Dong Ji, Enqiang Qin, Jing Xu, Dawei Zhang, Gregory Cheng, Yudong Wang, George Lau
 [1] 

188 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.007 sec